Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses current treatment challenges and strategies for managing psoriasis in the scalp, nails, and intertriginous areas, emphasizing the need for effective and well-tolerated long-term options, but reports no new clinical results.

This review critically assesses current topical therapies for scalp psoriasis and reports no new clinical results; the authors highlight the need for controlled trials to evaluate treatment efficacy.

This source reports that clascoterone cream has been approved in the U.S. for treating acne vulgaris in patients aged 12 and older, suggesting it works by competing with dihydrotestosterone at androgen receptors to mitigate acne's effects.

This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.

This source describes clascoterone, a new topical treatment for acne vulgaris that blocks androgen receptors to reduce sebaceous gland activity and inflammation, offering a lower risk of systemic side effects compared to oral treatments.

This source reports that clascoterone cream, a topical androgen receptor inhibitor, has shown effectiveness in treating facial acne vulgaris in patients 12 and older, with clinical trials indicating a favorable safety profile compared to systemic treatments, and potential for broader dermatological applications.

This study found that the once-daily gel combining calcipotriene and betamethasone dipropionate was more effective and faster in treating scalp psoriasis compared to individual treatments, with a similar safety profile.

This article lists the clinically important interactions and skin reactions of several drugs and substances, including THA, FK506, tamoxifen, tamsulosin, tartrazine, tea tree oil, temazepam, and temozolomide, but provides no new clinical results.

This case series involving 10 patients treated with clascoterone cream 1% for acne vulgaris found it effective and well-tolerated, regardless of severity, age, gender, or ethnicity, and noted additional benefits for related skin conditions.

This review discusses the clinical trials of clascoterone 1% cream for acne vulgaris and reports no new results; the authors highlight its novel role as a topical antiandrogen.

In this case series, treatment with clascoterone cream 1% was reported to be effective and well tolerated for diverse acne vulgaris patients, improving clinical outcomes whether used alone or in combination with other therapies, and addressing various other skin conditions.

This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.

This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.

This study found that cortexolone 17α-propionate (clascoterone) effectively inhibited androgen receptor-regulated transcription and IL-6 synthesis in scalp cells, potentially making it a promising candidate for topical treatment of androgenetic alopecia.

This study in Mexican adolescents with severe alopecia areata reported that oral tofacitinib treatment resulted in hair growth and reduced alopecia severity without serious adverse effects.

This study reported that clascoterone cream reduced inflammatory and noninflammatory acne lesions in a trial with 1440 white males and non-pregnant females, showing it was well tolerated in these participants.

This presentation highlighted future directions in acne care, emphasizing the roles of topical and oral antibiotics, as well as skin microbiome studies. It also described how clascoterone targets androgen receptors in hair follicles and sebaceous glands to reduce sebum production.

Clascoterone safely promotes hair growth similar to minoxidil.

This correspondence discusses clascoterone as a potential new treatment for androgenetic alopecia but reports no clinical results.

In this study, tacrolimus was as effective as clobetasol propionate in treating alopecia areata, suggesting it can serve as an alternative therapy option.

This study found that combining a potent steroid with a vitamin D analogue may offer more convenient treatment for localized alopecia areata than using a superpotent steroid alone, with comparable efficacy but fewer side effects.

In this randomized controlled trial, researchers observed that topical clobetasol propionate 0.05% was significantly more effective than topical tacrolimus 0.1% for treating alopecia areata, with a higher treatment success rate of 74.2% versus 45.2%, suggesting clobetasol as a preferred first-line topical therapy.

This randomized controlled trial found that topical clobetasol propionate 0.05% ointment is significantly more effective than topical tacrolimus 0.1% ointment in promoting hair regrowth in patients with alopecia areata, with effective results observed in 79.31% of clobetasol users compared to 44.82% of tacrolimus users.

This study found that among adults with severe alopecia areata, alopecia totalis, or alopecia universalis, oral tofacitinib was more effective than methotrexate in reducing hair loss over a 12-week period, though long-term safety and efficacy remain unestablished.

Clofazimine may be effective for treating ashy dermatosis.

This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

This article reviews triamcinolone acetonide as an intramuscular long-acting steroid therapy for dermatologic disorders but reports no new clinical results.